TrialThe Journal of clinical endocrinology and metabolism2014

A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis.

Johan Halse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.